Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

No writing assistance was utilized in the production of this manuscript. Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence increases with age. Current data suggest ...